Prelude Capital Management, LLC Argenx Se Transaction History

Prelude Capital Management, LLC

$1.57 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $101,673 - $151,803	-300 Reduced 15.38%	1,650 $627,000
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $129,272 - $191,950	350 Added 21.88%	1,950 $958,000
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $180,070 - $211,290	500 Added 45.45%	1,600 $623,000
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $370,995 - $448,051	-1,110 Reduced 50.23%	1,100 $409,000
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $136,525 - $160,521	399 Added 22.03%	2,210 $837,000
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $64,864 - $74,796	-189 Reduced 9.45%	1,811 $639,000
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $508 - $702	-2 Reduced 0.1%	2,000 $631,000
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $136,277 - $176,868	501 Added 33.38%	2,002 $701,000
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $295 - $350	1 Added 0.07%	1,501 $453,000
Q2 2021 Aug 16, 2021	BUY	$257.11 - $319.92 $385,665 - $479,880	1,500 New	1,500 $452,000
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $229,522 - $348,470	-2,109 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$106.59 - $164.21 $184,507 - $284,247	1,731 Added 457.94%	2,109 $339,000
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $8,838 - $11,739	-78 Reduced 17.11%	378 $43,000
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $138,690 - $170,745	-1,206 Reduced 72.56%	456 $65,000
Q1 2019 May 15, 2019	BUY	$98.85 - $134.59 $106,560 - $145,088	1,078 Added 184.59%	1,662 $207,000
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $16,143 - $27,784	-253 Reduced 30.23%	584 $56,000
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $21,215 - $27,153	281 Added 50.54%	837 $63,000
Q2 2018 Aug 14, 2018	SELL	$74.84 - $100.16 $16,839 - $22,536	-225 Reduced 28.81%	556 $46,000
Q1 2018 May 15, 2018	BUY	$56.95 - $85.19 $5,296 - $7,922	93 Added 13.52%	781 $63,000
Q4 2017 Feb 14, 2018	BUY	$22.57 - $63.56 $6,703 - $18,877	297 Added 75.96%	688 $43,000
Q3 2017 Nov 14, 2017	BUY	$19.81 - $22.61 $7,745 - $8,840	391	391 $9,000

Others Institutions Holding ARGX

# of Institutions

403

Shares Held

30.8M

Call Options Held

376K

Put Options Held

489K

Price T Rowe Associates Inc Baltimore, MD

5.82M
Shares

$3.82 Billion
0.36% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

3.51M
Shares

$2.31 Billion
2.99% of portfolio
Janus Henderson Group PLC London, X0

2.48M
Shares

$1.63 Billion
0.72% of portfolio
Capital World Investors Los Angeles, CA

1.7M
Shares

$1.12 Billion
0.15% of portfolio
Avoro Capital Advisors LLC New York, NY

1.24M
Shares

$813 Million
10.11% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $36.3B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Account